NSPR INSPIREMD INC

InspireMD to Announce Fourth Quarter and Full Year 2025 Financial Results

InspireMD to Announce Fourth Quarter and Full Year 2025 Financial Results

MIAMI, March 09, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its fourth quarter and full year 2025 financial results on Wednesday, March 18, 2026. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights.

A live audio webcast and an archive of the recording will be available through the Investors page of InspireMD’s corporate website at . Interested participants are encouraged to register more than 15 minutes before the start of the call.

About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MicroNet™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR.

We routinely post information that may be important to investors on our website. For more information, please visit .

Investor Contact:

Webb Campbell

Gilmartin Group LLC





EN
09/03/2026

Underlying

NSPRINSPIREMD INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on INSPIREMD INC

 PRESS RELEASE
Free
NSPR INSPIREMD INC

InspireMD to Announce Fourth Quarter and Full Year 2025 Financial Resu...

InspireMD to Announce Fourth Quarter and Full Year 2025 Financial Results MIAMI, March 09, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its fourth quarter and full year 2025 financial results on Wednesday, March 18, 2026. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. A live audio webcast and an archive of the recording will be available throu...

4h / 47m 1 EN
 PRESS RELEASE
Free
NSPR INSPIREMD INC

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c...

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MIAMI, Jan. 20, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board of Directors approved inducement grants to one (1) new non-executive employee in the aggregate amount of 36,118 shares of restricted stock (the “Inducement Grants”) outside of InspireMD’s 2021 Equity Incentive Plan, with a grant date as of January 14, 2026, as an i...

January 20, 2026 1 EN
 PRESS RELEASE
Free
NSPR INSPIREMD INC

InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manus...

InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC) The CGuard® Prime Carotid Stent System demonstrated the lowest 30-day and 1-year primary endpoint major adverse event rates of any pivotal study of carotid stenting (CAS) MIAMI, Jan. 12, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that results from the Company’s C-GUARDIANS pivotal trial have now been published in ...

January 12, 2026 1 EN
 PRESS RELEASE
Free
NSPR INSPIREMD INC

Landmark CREST-2 Study Published in the New England Journal of Medicin...

Landmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery Stenting Carotid artery stenting combined with medical therapy demonstrated a significantly lower stroke risk compared to intensive medical therapy alone in patients with severe asymptomatic carotid stenosis MIAMI, Nov. 24, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, welcomes the recent presentation and publication of CREST-2 data which demonstrated p...

November 24, 2025 1 EN
 PRESS RELEASE
Free
NSPR INSPIREMD INC

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c...

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MIAMI, Nov. 21, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board of Directors approved inducement grants to eight (8) new non-executive employees in the aggregate amount of 122,054 shares of restricted stock (the “Inducement Grants”) outside of InspireMD’s 2021 Equity Incentive Plan, with a grant date as of November 20, 2025, as...

November 21, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch